Early diagnosis of invasive fungal infections of caused by Aspergillus and other emerging mycelial fungi;Estado actual del diagnóstico precoz de las infecciones invasoras causadas por Aspergillus y otros hongos filamentosos emergentes

Revista Iberoamericana de Micologia

Volumn 24, Issue 3, 2007, Pages 187-197

  Del Palacio, Amalia ^a   Alhambra, Almudena ^a   Cuétara, Ma Soledad ^b   Pontón, José ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL SEVERO OCHOA   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

(1 3) D glucan; Diagnosis; Galactomannan; Invasive fungal infection; Mycelial fungi

Indexed keywords

ANTIGEN DETECTION; ASPERGILLOSIS; ASPERGILLUS; BLOOD SAMPLING; DIAGNOSTIC TEST; DISEASE MARKER; EARLY DIAGNOSIS; FUNGAL DETECTION; FUNGUS GROWTH; FUNGUS IDENTIFICATION; MYCELIAL GROWTH; NONHUMAN; REVIEW; SYSTEMIC MYCOSIS;

ASPERGILLUS; FUNGI;

EID: 35348944857     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1130-1406(07)70042-6     Document Type: Review

References (74)

1. Alexander BD, Pfaller MA. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 2006; 43: S15-S27.
2. Anaissie EJ. Trial design for mold-active agents: time to break the mold-aspergillosis in neutropenic adults. Clin Infect Dis 2007; 44: 1298-1306.
3. Ascioglu SJ, Rex JH, de Pauw B, Bennet JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and haematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
4. Aubry A, Porcher R, Bottero J, Touratier S, Leblanc T, Brethon B, Rousselot P, Raffoux E, Menotti J, Derouin F, Ribaud P, Sulahian A. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with β-Lactam antibiotics in patients with hematological disorders. J Clin Microbiol 2006; 44: 389-394.
5. Bart-Delabasse E, Basile M, Al Jijakli A, Souville D, Gay F, Philippe B, Bossi P, Danis M, Vernant JP, Datry A. Detection of Aspergillus galactomannan antigenemia to determine biological and clinical implications of beta-lactam treatments. J Clin Microbiol 2005; 43: 5214-5220.
6. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyannis DP. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy over a 15 year period (1989-2003). Haematologica 2006; 91: 986-989.
7. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst HA, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R; AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high loading dose regimen with standard dosing (ambiload trial). Clin Infect Dis 2007; 44: 1289-1297.
8. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullman AJ, Walsh TJ, Heygott D, Holowiecki J, Stockellberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-359.
9. Cuétara MS, Alhambra A, Moreno JM, Postigo C, Moragues MD, Pontón J, del Palacio A. Invasive aspergillosis due to subungueal onychomycosis during treatment for non-Hodgkin lymphoma. Br J Dermatol 2006; 154: 1199-1219.
10. Dalle F, Charles PE, Blanc K, Caillot D, Chavanet P, Dromer F, Bonnin A. Cryptococcus neoformans galactotoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus galactomannan. J Clin Microbiol 2005; 43: 2929-2931.
11. de Pauw BE, Patterson TF. Should consensus guidelines specific criteria for the diagnosis of invasive fungal infection be changed? Clin Infect Dis 2005; 4: S377-S380.
12. de Pauw B. Between over and undertreament of invasive fungal diseese. Clin Infect Dis 2005; 41: 1251-1253.
13. del Palacio A, Alhambra A, Cuétara MS. Factures de riesgo de la candidiasis invasora: estratificación. Rev Iberoam Micol 2006; 23: 29-31.
14. Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a way to go. Clin Infect Dis 2006; 42: 487-489.
15. Douwes J. (1-3)-beta-D glucans and respiratory health: a review of the scientific evidence. Indoor Air 2005; 15: 160-169.
16. El Saleeby C, Allison K, Knapp K, Walsh T, Hayden R. Discordant rise in galactomannan antigenemia in a patient with resolving aspergillosis, renal failure, and ongoing hemodiálisis. J Clin Microbiol 2005; 43: 3560-3563.
17. Food and Drug Administration. Medical devices, immunology and microbiology devices; classification of the beta-glucan serological assay. Final rule. Fed Regist 2004; 69: 56934-56936.
18. Hachem R, Sumoza D, Hanna H, Girgawy E, Munsell M. Raad I. Clinical and radiologic predictors of invasive pulmonary aspergillosis in cancer patients. Should the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria be revised? Cancer 2006; 106: 1581-1586.
19. Hope W, Walsh T, Denning D. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005; 5: 609-622.
20. Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005; 43: S207-S238.
21. Husain S, Alexander BD, Muñoz P, Avery RK, Houston S, Pruett T, Jacobs R, Dominguez EA, Tollemar JG, Baumgarten K, Yu CM, Wagener MM, Linden P, Kusne S, Singh N. Oportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non Aspergillus mycelial fungi. Clin Infect Dis 2003; 37: 221-229.
22. Ikemura K, Ikegami K, Shimazu T, Yoshioka T, Sugimoto T. False positive result in Limulus test caused by Limulus amebocyte lysate reactive material in immunoglobulin products. J Clin Microbiol 1989; 27: 1965-1968.
23. Kakinuma A, Asano T, Torii H, Sugino Y. Gelation of Limulus amoebocyte lysate by an antitumor (1-3)-beta-D glucan. Biochem Biophys Res Com 1981; 101: 434-439.
24. Kato A, Takita T, Furuhashi M, Takanashi T, Maruyama Y, Hishida A. Elevation of blood (1-3)-beta-Dglucan concentrations in hemodiálisis patients. Nephron 2001; 89: 15-19.
25. Kawazu M, Kanda Y, Nannya Y, Aoki K, Kwrokawa M, Chiba S, Motokura T, Hirai H, Ogawa S. Prospective comparation of the diagnostic potential of real-time PCR, double-sanwich enzyme-linked immunosorbent assay for galactomannan, and a (1-3)-beta-D glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004; 42: 2733-2741.
26. Klont RR, Meis JFG, Verweij PE. Critical assessment of issues in the diagnosis of invasive aspergillosis. Clin Microbiol Infect 2001; 7: S32-S37.
27. Klont R, Mennink-Kersten M, Ruegebrink D, Rijs A, Blijlevens N, Donnelly JP, Verweij P. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis 2006; 43: e23-e25.
28. Lewis RE, Wiederhold NP, Chi J, Han XY, Komanduri KV, Kontoyiannis DP, Prince RA. Detection of gliotoxin in experimental and human aspergillosis. Infect Immun 2005; 73: 635-637.
29. Lewis RE, Wiederhold NP, Lionakis MS, Prince RA, Kontoyiannis DP. Frequency and species distribution of gliotoxin producing Aspergillus isolates recovered from patients at a tertiary care center. J Clin Microbiol 2005; 43: 6120-6122.
30. Maertens J, Deeren D, Dierickx D, Theunissen K. Preemptive antifungal therapy: still a way to go. Curr Opin Infect Dis 2006; 19: 551-556.
31. Maertens J, Glasmacher A, Selleslag D, Ngai A, Ryan D, Layton M, Taylor A, Sable C, Kartsonis N. Evaluation of serum sándwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin Infect Dis 2005; 41: e9-e14.
32. Maertens JA, Theunissen K, Deeren D, Meersseman W, Van Eldere J. Defining a case of invasive aspergillosis by serum galactomannan. Med Mycol 2006; 44: S173-S178.
33. Maertens J, Theunissen K, Lodewyck T, Lagrou K, Van Eldere J. Advances in the serological diagnosis of invasive aspergillosis infections in patients with haematological disorders. Mycoses 2007; 50: S1-S17.
34. Maertens J, Theunissen K, Verhoef G, Werschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhagen J, Boogaerts M, Van Eldere J. Galactomannan and computed tomography-bassed preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-1250.
35. Meertens JA, Klont R, Masson C, Theunissen K, Meersseman W, Lagrou V, Heinen C, Crepin B, Vand Eldere J, Tabouret M, Donelly JP, Verweij PE. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 2007; 44: 1329-1336.
36. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomann enzyme immunoassay. Clin Infect Dis 2005; 40: 1762-1769.
37. Marr KA, Leisenring W. Design issues in studies evaluating diagnostic tests for aspergillosis. Clin Infect Dis 2005; 41: S381-386.
38. McLintock LA, Jordanides NE, Allan EK, Copland M, Steward K, Parker A, Devaney M, Holyoake M, Jones BI. The use of a risk group stratification in the management of invasive fungal infection: a prospective validation. Br J Haematol 2004; 124: 403-404.
39. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijnaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Repir Crit Care Med 2004; 170: 621-625.
40. Menninck-Kersten MA, Ruegebrink D, Klont RR, Warris A, Gavini F, Opden Camp JM, Verweij PE. Bifidobacterial lipoglycan as a new cause for false positive Platelia Aspergillus enzyme-linked immunosorbent assay reactivity. J Clin Microbiol 2005; 43: 2929-2931.
41. Mennink-Kersten M, Warris A, Verweij P. (1-3)-beta-D glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med 2006; 354: 2834-2835.
42. Metan G, Durusu M, Uzun O. False positivity for Aspergillus antigenemia with amoxicillin-clavulanic acid. J Clin Microbiol 2005 43: 2548-2549.
43. Miceli MH, Grazziuti M, Woods G, Diaz J, Krishna S, Kiwan E, Syed M, Barlogie B, Anaissie E. Outcome of invasive aspergillosis (IA) in 30 patients with hematological cancer: immunity is (almost)everything. Blood 2006; 108: 5314.
44. Miceli MH, Anaissie E. When a paradoxical increase in serum galactomannan antigen during caspofungin therapy is not paradoxical after all. Clin Infect Dis 2007; 44: 757-760.
45. Moreno JM, Alhambra A, Cuétara MS, Ortiz MC, Pontón J, del Palacio Perez Medel A, del Palacio A. Incidence of invasive fungal infection in adult haematological malignancy: a prospective validation of a risk stratification scheme. Br J Haematol 2006; 134: 343-345.
46. Murashige N, Kami M, Kishi Y, Fujisaki G, Tanosaki R. False-positive results of Aspergillus enzyme linked immunosorbent assays for a patient with gastrointestinal graft versus host disease taking a nutrient containing soybean protein. Clin Infect Dis 2005; 40: 333-334.
47. Nakao A, Yasui M, Kawagoe T, Tamura H, Tamaka S, Tagaki H. False positive endotoxemia derives from gauze glucan after hepatectomy for hepatocellular carcinoma with cirrhosis. Hepatogastroenterology 1997; 44: 1413-1418.
48. Nucci M. Emerging moulds: Fusarium, Scedosporium and zygomycetes in transplant recipients. Curr Opinion Infect Dis 2003; 16: 607-612.
49. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelmen MA, Rex JH, Ostrosky-Zeichner L. Beta-D-glucan as a diagnostic adjunt for invasive fungal infections: validation, cutoff developement, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199-205.
50. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schritt R, Tamura H, Finkelman MA, Rex JH. Multicenter clinica evaluation of the (1-3)-beta-D glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-659.
51. Paphitou NI, Ostrosky Zeichner L, Rex JH. Rules for identifying patients at incresed risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005; 43: 235-243.
52. Pazos C, del Palacio A. Diagnóstico precoz de la aspergilosis invasora en enfermos neutropénicos mediante la detección bisemanal de galactomanano en suero con Platelia Aspergillus. Rev Iberoam Micol 2003; 20: 99-102.
53. Pazos C, Moragues MD, Quindós G, Pontón J, del Palacio A. Diagnostic pontential of (1-3)-beta-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev Iberoam Micol 2006; 23: 209-215.
54. Pazos C, Pontón J, del Palacio A. Contribution of (1-3) beta-D glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergilosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43: 299-305.
55. Pfeiffer C, Fine J, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a metaanalysis. Clin Infect Dis 2005; 42: 1417-1427.
56. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1-3)-beta-D glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43: 5957-5962.
57. Pontón J (Ed). Guía de bolsillo de la Aspergilosis invasora. Bilbao, Revista Iberoamericana de Micología, 2003: 1-105.
58. Pontón J, del Palacio A. Influence of Candida colonization on the (1-3)-beta-D glucan assay. Clin Infect Dis 2006; 43: 263-264.
59. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000; 110: 273-284.
60. Rex JH. Galactomannan and the diagnosis of invasive aspergillosis. Clin Infect Dis 2006; 42: 1428-1430.
61. Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 2005; 56: 5-11.
62. Rickerts V, Mousset S, Lembrecht E, Tintelnot K, Schwerdtfeger R, Presterl E, Jacobi V, Just-Nübling G, Bialek R. Comparison of hispatological analysis, culture, and Polymerase Chain Reaction Assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis 2007; 44: 1078-1083.
63. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-653.
64. Singh N, Paterson DL: Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44-69.
65. Subirá M, Martino R, Rovira M, Vazquez L, Serrano D, de la Cámara R. Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy confirmed invasive aspergillosis. Ann Hematol 2003; 82: 80-82.
66. Ullmann AJ, Lipton JH, Vesole D, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo M, Reddy V, Boparai N, Predicone L, Patino H, Durrant S. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347.
67. Upton A, Gugel A, Leisenring W, Limaye A, Alexander B, Hayden R, Marr KA. Reproductibility of low galactomanannan enzyme immunoassay index values tested in multiple laboratories. J Clin Microbiol 2005; 43: 4796-4800.
68. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-540.
69. Upton A, Leisenring W, Marr K. (1-3) beta-D glucan assay in the diagnosis of invasive fungal infections. Clin Infect Dis 2006; 42: 1054-1056.
70. Vanderwoude KH, Vogaleaers D, Blot SI. Aspergillosis in the ICU the new 21st century problem? Med Mycol 2006; 44: S71-S76
71. Verweij P. Advances in diagnostic testing. Med Mycol 2005; 43: S121-S124.
72. Weisser M, Rausch C, Simick M, Sendi P, Steffen I, Buitrago C, Sonnet S, Gratwohl A, Passweg J, Fluckiger V. Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with haematological malignancies. Clin Infect Dis 41: 1143-1149.
73. Wilson ML. Infectious diseases and the autopsy. Clin Infect Dis 2006; 43: 602-603.
74. Woods G, Miceli M, Grazziutti M, Krishna S, Syed N, Kiwan E, Rahman M, Barlogie B, Anaissie E. Validation of serum Aspergillus galactomannan index as a surrogate endpoint for outcome of invasive aspergillosis: clinical and research implications. Blood 2006; 108: 2861.